Virbac Stock Rebounds by 2.75% to €355, Defending its Key Moving Average
The veterinary laboratory in Carros gains 2.75% to €355 in mid-morning trading, in a rising Parisian market. The SBF 120 index is up by 0.75% at the same time. Over a year, the stock maintains a lead of 13.96%.
The Stock Moves Above its MM200 but Struggles Below its 20-Day Average
Virbac stock approaches its 50-day moving average (€356.23), while remaining 2.52% below its MM20 (€364.18). Today's rebound allows the price to stay above the MM200 at €347.18, a long-term trend marker that has been preserved for several sessions. The RSI at 41 remains neutral, showing no signs of exhaustion. The price is in the lower part of the Bollinger Bands, at 34% of the range, between a lower bound of €336.35 and an upper bound of €392.00. The support at €339.00, close to this lower bound, was not tested during the session. The one-month volatility stands at 7.35, consistent with levels observed in recent weeks on the stock. Today's rise is part of a collective movement on the SBF 120, where Atos, Capgemini, and Exosens lead the gains.
Focus on the General Assembly on June 26 and the Q2 Revenue Release in July
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Following the publication of the first quarter revenue on April 20, amounting to €384 million (+7.7% at constant scope and exchange rates), the financial calendar points to the next events being the ordinary general assembly on June 26, 2026, followed by the second quarter revenue release on July 20, 2026. The next bullish technical milestone identified in the indicators is the resistance at €384.00, which the price has not revisited for several sessions.
SectorPharmacie et biotechnologies›Vaccins et laboratoires de recherche
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 768 millions d'euros
Quarterly revenue: 768 millions d'euros
Guidance from the release
notre forte dynamique du premier semestre (+7,4 % de croissance) nous permet de viser la borne haute de notre fourchette
Outlook / guidance
Expected revenue: 1 575 millions d'euros
Management commentary: la borne haute de notre fourchette initiale de croissance du chiffre d'affaires (comprise entre 5,5 % et 7,5 % à PCC) et une marge de résultat opérationnel courant ajusté d'environ 17 % à PCC
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
